The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Pravachol     (3R,5R)-7-[(1S,2R,6S,8S,8aS)- 6-hydroxy-2...

Synonyms: Pravator, Eptastatin, Vasten, pravastatin, RMS-431, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of pravastatin


Psychiatry related information on pravastatin


High impact information on pravastatin


Chemical compound and disease context of pravastatin


Biological context of pravastatin


Anatomical context of pravastatin


Associations of pravastatin with other chemical compounds


Gene context of pravastatin


Analytical, diagnostic and therapeutic context of pravastatin


  1. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. Packard, C.J., O'Reilly, D.S., Caslake, M.J., McMahon, A.D., Ford, I., Cooney, J., Macphee, C.H., Suckling, K.E., Krishna, M., Wilkinson, F.E., Rumley, A., Lowe, G.D. N. Engl. J. Med. (2000) [Pubmed]
  2. The effect of pravastatin on coronary events after myocardial infarction. Modan, B., Kuller, L.H. N. Engl. J. Med. (1997) [Pubmed]
  3. Prevention of coronary heart disease with pravastatin. Samani, N.J., de Bono, D.P. N. Engl. J. Med. (1996) [Pubmed]
  4. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. Kuivenhoven, J.A., Jukema, J.W., Zwinderman, A.H., de Knijff, P., McPherson, R., Bruschke, A.V., Lie, K.I., Kastelein, J.J. N. Engl. J. Med. (1998) [Pubmed]
  5. Pravastatin therapy and the risk of stroke. White, H.D., Simes, R.J., Anderson, N.E., Hankey, G.J., Watson, J.D., Hunt, D., Colquhoun, D.M., Glasziou, P., MacMahon, S., Kirby, A.C., West, M.J., Tonkin, A.M. N. Engl. J. Med. (2000) [Pubmed]
  6. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Haydont, V., Bourgier, C., Pocard, M., Lusinchi, A., Aigueperse, J., Mathé, D., Bourhis, J., Vozenin-Brotons, M.C. Clin. Cancer Res. (2007) [Pubmed]
  7. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin. Lechleitner, M., Hoppichler, F., Konwalinka, G., Patsch, J.R., Braunsteiner, H. Lancet (1992) [Pubmed]
  8. Purification and regulation of mevalonate kinase from rat liver. Tanaka, R.D., Schafer, B.L., Lee, L.Y., Freudenberger, J.S., Mosley, S.T. J. Biol. Chem. (1990) [Pubmed]
  9. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Vgontzas, A.N., Kales, A., Bixler, E.O., Manfredi, R.L., Tyson, K.L. Clin. Pharmacol. Ther. (1991) [Pubmed]
  10. Decline in total cerebral blood flow is linked with increase in periventricular but not deep white matter hyperintensities. Ten Dam, V.H., van den Heuvel, D.M., de Craen, A.J., Bollen, E.L., Murray, H.M., Westendorp, R.G., Blauw, G.J., van Buchem, M.A. Radiology (2007) [Pubmed]
  11. Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects. Ogawa, K., Hasegawa, S., Udaka, Y., Nara, K., Iwai, S., Oguchi, K. Journal of clinical pharmacology. (2003) [Pubmed]
  12. Pravastatin and coronary heart disease. Bloom, J.M. N. Engl. J. Med. (1999) [Pubmed]
  13. Effect of pravastatin on outcomes after cardiac transplantation. Kobashigawa, J.A., Katznelson, S., Laks, H., Johnson, J.A., Yeatman, L., Wang, X.M., Chia, D., Terasaki, P.I., Sabad, A., Cogert, G.A. N. Engl. J. Med. (1995) [Pubmed]
  14. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R., Braunwald, E. N. Engl. J. Med. (1996) [Pubmed]
  15. Lack of hypotension with lovastatin and pravastatin. Kostis, J.B., Wilson, A.C. Lancet (1991) [Pubmed]
  16. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Katano, H., Pesnicak, L., Cohen, J.I. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  17. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Goldberg, R.B., Mellies, M.J., Sacks, F.M., Moyé, L.A., Howard, B.V., Howard, W.J., Davis, B.R., Cole, T.G., Pfeffer, M.A., Braunwald, E. Circulation (1998) [Pubmed]
  18. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Egashira, K., Hirooka, Y., Kai, H., Sugimachi, M., Suzuki, S., Inou, T., Takeshita, A. Circulation (1994) [Pubmed]
  19. Preventing the next event in the elderly: the PROSPER perspective. Shepherd, J. Atherosclerosis. Supplements. (2003) [Pubmed]
  20. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Dunzendorfer, S., Rothbucher, D., Schratzberger, P., Reinisch, N., Kähler, C.M., Wiedermann, C.J. Circ. Res. (1997) [Pubmed]
  21. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. Mason, R.P., Walter, M.F., Day, C.A., Jacob, R.F. J. Biol. Chem. (2006) [Pubmed]
  22. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. de Grooth, G.J., Zerba, K.E., Huang, S.P., Tsuchihashi, Z., Kirchgessner, T., Belder, R., Vishnupad, P., Hu, B., Klerkx, A.H., Zwinderman, A.H., Jukema, J.W., Sacks, F.M., Kastelein, J.J., Kuivenhoven, J.A. J. Am. Coll. Cardiol. (2004) [Pubmed]
  23. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Salonen, R., Nyyssönen, K., Porkkala, E., Rummukainen, J., Belder, R., Park, J.S., Salonen, J.T. Circulation (1995) [Pubmed]
  24. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes. Tanaka, M., Jingami, H., Otani, H., Cho, M., Ueda, Y., Arai, H., Nagano, Y., Doi, T., Yokode, M., Kita, T. J. Biol. Chem. (1993) [Pubmed]
  25. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Sacks, F.M., Pasternak, R.C., Gibson, C.M., Rosner, B., Stone, P.H. Lancet (1994) [Pubmed]
  26. Effects of lovastatin and pravastatin on coronary artery disease. Goldstein, M.R. Ann. Intern. Med. (1994) [Pubmed]
  27. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Nagashima, T., Okazaki, H., Yudoh, K., Matsuno, H., Minota, S. Arthritis Rheum. (2006) [Pubmed]
  28. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. Aberg, J.A., Rosenkranz, S.L., Fichtenbaum, C.J., Alston, B.L., Brobst, S.W., Segal, Y., Gerber, J.G. AIDS (2006) [Pubmed]
  29. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. Mallon, P.W., Miller, J., Kovacic, J.C., Kent-Hughes, J., Norris, R., Samaras, K., Feneley, M.P., Cooper, D.A., Carr, A. AIDS (2006) [Pubmed]
  30. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Becquemont, L., Neuvonen, M., Verstuyft, C., Jaillon, P., Letierce, A., Neuvonen, P.J., Funck-Brentano, C. Clin. Pharmacol. Ther. (2007) [Pubmed]
  31. Neuroprotection by pravastatin in acute ischemic stroke in rats. Berger, C., Xia, F., Maurer, M.H., Schwab, S. Brain. Res. Rev (2008) [Pubmed]
  32. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). Sasaki, M., Suzuki, H., Ito, K., Abe, T., Sugiyama, Y. J. Biol. Chem. (2002) [Pubmed]
  33. Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes. Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression. Tanaka, T., Tatsuno, I., Noguchi, Y., Uchida, D., Oeda, T., Narumiya, S., Yasuda, T., Higashi, H., Kitagawa, M., Nakayama, K., Saito, Y., Hirai, A. J. Biol. Chem. (1998) [Pubmed]
  34. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Guérin, M., Dolphin, P.J., Talussot, C., Gardette, J., Berthézène, F., Chapman, M.J. Arterioscler. Thromb. Vasc. Biol. (1995) [Pubmed]
  35. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Mazzu, A.L., Lasseter, K.C., Shamblen, E.C., Agarwal, V., Lettieri, J., Sundaresen, P. Clin. Pharmacol. Ther. (2000) [Pubmed]
  36. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Igel, M., Arnold, K.A., Niemi, M., Hofmann, U., Schwab, M., Lütjohann, D., von Bergmann, K., Eichelbaum, M., Kivistö, K.T. Clin. Pharmacol. Ther. (2006) [Pubmed]
  37. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H., Packard, C.J. N. Engl. J. Med. (1995) [Pubmed]
  38. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. Reihnér, E., Rudling, M., Ståhlberg, D., Berglund, L., Ewerth, S., Björkhem, I., Einarsson, K., Angelin, B. N. Engl. J. Med. (1990) [Pubmed]
WikiGenes - Universities